SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Cannabis >

Zynerba Pharmaceuticals (ZYNE)

ZYNE RSS Feed
Add ZYNE Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 12/14/2017 9:47:31 AM - Followers: 65 - Board type: Free - Posts Today: 1


Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome. The Company's ZYN002 is synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear that is designed to provide controlled drug delivery with once- or twice-daily dosing. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The Company intends to test the ZYN001 patch for application to the arm, back and thigh. The Company intends to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.

Investor Relations

Corporate Profile

Zynerba (NASDAQ: ZYNE) is pioneering the development of patent-protected, next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its two lead product candidates in development include ZYN002 and ZYN001, which are being evaluated in five indications. ZYN002 is the first and only synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In June 2016, the company initiated the STAR 1 Phase 2 clinical trial in refractory epilepsy patients and in August 2016, initiated the STOP Phase 2 clinical trial in patients with osteoarthritis of the knee. A Phase 2 clinical trial in patients with Fragile X syndrome will be initiated in the second half of 2016. 

ZYN001, a prodrug of THC that enables transdermal delivery through the skin and circulatory system via a patch, is in preclinical development. A Phase 1 clinical trial is planned in the first half of 2017.

In August 2015, Zynerba completed an initial public offering, raising net proceeds of $42.1 million. As of June 30, 2016, cash and cash equivalents totaled $32.1 million, which is projected to fund five Phase 2 clinical trials through 2017.





Zynerba Pharmaceuticals, Inc., (Nasdaq: ZYNE) announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Zynerba. In addition, Zynerba has granted the underwriters an option to purchase up to 450,000 additional shares of common stock at the public offering price, less the underwriting discount. Zynerba's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the symbol "ZYNE" on August 5, 2015.

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering, and Canaccord Genuity Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. This offering is being made only by means of a prospectus.



Extremely low float:

Fundamentals

A table providing the fundamentals of the stock
EPS (TTM) 9/30/2016 | -2.47
P/E Ratio 9/30/2016 | --
Market Cap Micro Cap | 146M
Shares Outstanding 9.95M
Float 7.2M

 

SureTrader
Interactive Brokers Advertisement
ZYNE
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ZYNE News: Dangerous Opioid Side Effects Shift Market Focus to Cannabis for Chronic Pain 12/13/2017 08:45:00 AM
ZYNE News: Advanced Biosynthesis Setting New Standards for Cannabinoid-based Pain Management 12/06/2017 08:45:00 AM
ZYNE News: Current Report Filing (8-k) 12/04/2017 07:31:33 AM
ZYNE News: Zynerba Pharmaceuticals Announces New ZYN002 Data from STAR 1 and STAR 2 Studies in Patients with Focal Seizures at the 2017 ... 12/03/2017 12:01:00 PM
ZYNE News: Zynerba Pharmaceuticals Announces Poster Presentation at the 2017 Annual Meeting of the American Epilepsy Society (AES) 11/21/2017 09:00:00 AM
PostSubject
#1013   Is that a possible cup and handle pattern MD-420 12/14/17 09:47:31 AM
#1012   Yup! GO MYDX!!!!! Tabbysan 12/08/17 12:59:23 PM
#1010   I didn't read the release, but the market cjarmstrong 12/06/17 08:14:44 PM
#1009   Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), a surfgreen 12/06/17 11:57:51 AM
#1008   Was the news not that good. Looks like MD-420 12/06/17 10:08:21 AM
#1007   I’m not into the day to day on WolfOfGrnStreet 12/05/17 07:04:22 PM
#1006   I thought the nees was good. Maybe shorts MD-420 12/04/17 08:10:24 PM
#1005   The future is coming. This stock soars imo. WolfOfGrnStreet 12/04/17 07:35:15 PM
#1004   Market does not like them Pursuing and spending money AntonChigurh 12/04/17 03:34:45 PM
#1003   WTF Seems like inside information always leaks on surfgreen 12/04/17 01:13:09 PM
#1002   Shorts are gonna be cooked. Glad I bought MD-420 12/04/17 08:44:01 AM
#1001   16's premarket a surfer 12/04/17 08:06:03 AM
#1000   Yes you did. How did you know? We should MD-420 12/04/17 06:06:11 AM
#999   Told you so Bescaredxx 12/03/17 10:40:24 PM
#998   $ZYNE$- Excellent! Clinically Meaningful Median Reduction in Seizures surfgreen 12/03/17 03:22:57 PM
#997   This is in early stages don’t forget. If WolfOfGrnStreet 12/02/17 11:43:53 PM
#996   Sure as hell beats 6 bucks!! a surfer 12/01/17 08:25:10 PM
#995   Zyne. I’ll see you guys at the $50 WolfOfGrnStreet 11/30/17 09:49:06 PM
#994   You will see in sunday! :) Bescaredxx 11/30/17 03:11:45 PM
#993   What news is due? surfgreen 11/30/17 03:10:40 PM
#992   News out on sunday... BUY buy BUY Bescaredxx 11/30/17 11:17:50 AM
#991   This is about to blow sky high. MD-420 11/30/17 10:57:21 AM
#990   Love this recovery! $zyne Cbdpotential 11/23/17 10:42:21 PM
#989   True! a surfer 11/21/17 12:34:57 PM
#988   Who knows. The last testing news was highly MD-420 11/21/17 12:14:50 PM
#987   I am pleasantly surprised. I would think a surfer 11/21/17 12:11:07 PM
#986   I think this is headed back to the MD-420 11/20/17 09:36:45 AM
#985   I'm riding 6s and 7s. Almost sold on MD-420 11/17/17 04:17:50 AM
#984   S*** in one hand and wish in the WolfOfGrnStreet 11/16/17 03:29:59 PM
#983   I need this back at 6!!! Gregwit 11/16/17 02:26:23 PM
#982   15s coming soon. Maybe today. MD-420 11/15/17 08:13:21 AM
#981   Did i not tell you? Nothing but Bescaredxx 11/14/17 11:55:23 PM
#980   Looking sold after today. Expecting 15s by thanksgiving. MD-420 11/14/17 10:15:37 PM
#979   Impressive Q-10. Plenty of cash low O/S and surfgreen 11/14/17 05:51:56 PM
#978   See you all at the $100 mark eventually! WolfOfGrnStreet 11/11/17 07:16:47 PM
#977   $ZYNE$ Kaboom-Good news coming surfgreen 11/10/17 11:22:42 AM
#976   Yes WolfOfGrnStreet 11/09/17 07:57:02 PM
#975   News 13-14th Earnings and company up date! Everything Bescaredxx 11/09/17 04:32:40 PM
#974   $ZYNE$ nice uptrend surfgreen 11/09/17 01:35:40 PM
#972   This has woken up today. Glad I held. MD-420 11/06/17 09:58:51 AM
#971   Looks like insider Michael Rapp added a total LittleBird 10/27/17 11:33:46 AM
#970   Bored bored. We're just waiting for more catalysts LittleBird 10/26/17 10:39:02 AM
#969   Here's some incredibly uplifting news major investor Michael LittleBird 10/24/17 10:44:42 AM
#968   Holding up well! :-) $zyne Cbdpotential 10/23/17 11:53:52 PM
#967   FYI, the only partnership plans will be way Bescaredxx 10/22/17 07:18:17 PM
#966   CEO of UNIVEC Dr David Dalton has connections Smittytnt 10/22/17 12:30:21 PM
#965   Volume is insanely low the last couple of LittleBird 10/18/17 10:41:13 AM
#964   Buy stocky101 10/17/17 03:43:04 PM
#963   But the bounce $12plus tomorrow, it’s a head stocky101 10/17/17 03:42:28 PM
#962   I wish they would hurry up and tell PENNIEStoSTACKS 10/17/17 01:19:45 PM
PostSubject